Eplerenone Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Eplerenone Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
184
Registered trials
50
Result records
21
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Eplerenone can convert its Small molecule drug profile and MR biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Eplerenone (query alias: eplerenone) |
|---|---|
| Modality / target | Small molecule drug; MR; MR antagonists |
| Highest global status | Approved |
| Originator | Pfizer Inc. |
| Active developers | Pfizer Inc., Baxter Deutschland GmbH, Viatris Pharmaceutical Co. Ltd. |
The MCP disease footprint includes Acute myocardial infarction, Chronic heart failure, Left ventricular systolic dysfunction. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07539259 | Phase 2 | Not yet recruiting | 445 | Change in the left ventricular mass indexed from pre Aortic Valve Replacement (AVR) to 12 months post AVR |
| NCT07345845 | Early Phase 1 | Active, not recruiting | 40 | Change in microvascular endothelial function following local eplerenone treatment compared to placebo treatment measured by laser-Doppler flowmetry |
| ChiCTR2600122943 | Not Applicable | Not yet recruiting | 40 | Global Longitudinal Strain |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
An Open-label, Randomized, 3-arm, Parallel-group, Positive- and Negative-arm Controlled Study to Evaluate the Mineralocorticoid Receptor Antagonism Effect of Vamorolone in Healthy Subjects
Phase 1; n=30; evaluation: not stated. Reported fields: Day 1; 24-9h predose (Baseline)(Geometric Mean) = 0.98207 log10(10*Na/K) (Standard Deviation, 1.290309); Day 1; 24-9h predose (Baseline)(Geometric Mean) = 1.04238 log10(10*Na/K) (Standard Deviation, 1.407236); -
Hypertension and Striatin Gene Structure Related to Aldo Phenotype
Phase 4; n=90; evaluation: not stated. Reported fields: visit 2 systolic bp(Mean) = 148.5 mm hg (Standard Deviation, 10.5); visit 2 systolic bp(Mean) = 144.2 mm hg (Standard Deviation, 15); -
Mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: a systematic review and network meta-analysis of 32 randomized trials
Not Applicable; n=15685; evaluation: Positive. Reported fields: HF hospitalization: HR = 0.61(95.0% CI, 0.43 - 0.86); HF hospitalization: HR = 0.61(95.0% CI, 0.43 - 0.86); HF hospitalization: HR = 0.61(95.0% CI, 0.43 - 0.86)
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Eplerenone addresses Acute myocardial infarction, Chronic heart failure, Left ventricular systolic dysfunction. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 21 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: MR records as comparable precedents only.
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2025-05-21 | Daewon Pharm signs exclusive distribution deal with Bayer Korea for 2 hormone replacement therapies | Approved | Financial terms not disclosed |
| 2024-06-12 | Lupin and Fuji Sign License and Supply Agreement for Commercialization of Nextstellis™ in Vietnam and Philippines | Approved | Financial terms not disclosed |
| 2024-01-17 | Sun Pharma and Bayer sign marketing and distribution agreement for second brand of Finerenone in India | Approved | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Application of eplerenone in preparation of medicine for treating rheumatoid arthritis”. The milestone feed surfaced a patent-application signal described as “Application of eplerenone in preparation of medicine for treating type 1 diabetes”. The milestone feed surfaced a patent-application signal described as “Stable pharmaceutical compositions of eplerenone”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
